Serum CA125 concentration as a predictor of peritoneal dissemination of colorectal cancer in men and women

AbstractPeritoneal dissemination (PD) of cancer is difficult to diagnose. Previous reports have shown that carbohydrate antigen 125 (CA125) is a sensitive marker of PD of gastric cancer. However, CA125 has not been evaluated as a marker of colorectal cancer (CRC), and its accuracy in men is controversial. The aim of this study was to compare the ability of CA125 and carcinoembryonic antigen (CEA) to predict PD of CRC in men and women.Preoperative CA125 and CEA concentrations were measured in 853 people (510 men, 343 women) over 10 years. PD was confirmed intraoperatively in 57 patients. The predictive ability was compared between CA125 and CEA.Compared with CEA, CA125 concentration had a lower sensitivity, higher specificity, and diagnostic accuracy, and significantly greater area under the curve. Further analysis of CA125's sensitivity and specificity among CEA-negative group (n = 514) showed acceptable sensitivity (57.1%) and good specificity (92.0%). In men and women, CA125 concentration did not increase with stage from I to IV unless PD was present (P < 0.001). CEA concentration was increased in women with metastasis with PD (P < 0.001) or without PD (P < 0.001), but was increased only in men with metastasis without PD (P < 0.01). CA125 concentration correlated with PD grade for men and women, but CEA concentration correlated with grade only in women.When analyzed according to the primary tumor site, CA125 concentration in men did not differ between patients with the primary site in the right or left colon, or the rectum, regardless of PD status. By contrast, CA125 concentration differed between PD-positive and PD-negative patients with cancer in the right (P < 0.001) or left (P < 0.001) colon but not in the rectum. CEA concentration in men did not differ according to the primary site or PD status. In women, CA125 and CEA concentrations differed significantly between the PD-positive and PD-negative groups in patients with the primary tumor in the right (P < 0.001) or left (P < 0.001) colon; tumor sites did not differ between the PD-positive and PD-negative groups.These findings suggest that CA125 is a better tumor marker than CEA for predicting PD of CRC in both men and women.

[1]  Z. Estrov,et al.  CA 125: a clinically useful tumor marker in the management of colorectal carcinoma metastatic to the liver in patients with normal carcinoembryonic antigen. , 2000, American journal of clinical oncology.

[2]  Yu Bai,et al.  High serum carbohydrate antigen 125 concentration can predict serous effusion but not gastrointestinal malignancy in male patients , 2014, Tumor Biology.

[3]  H. Miyata,et al.  Prognostic Impact of Primary Tumor Resection and Lymph Node Dissection in Stage IV Colorectal Cancer with Unresectable Metastasis: A Propensity Score Analysis in a Multicenter Retrospective Study , 2014, Annals of Surgical Oncology.

[4]  J. Pelz,et al.  American Society of peritoneal surface malignancies opinion statement on defining expectations from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in patients with colorectal cancer , 2014, Journal of surgical oncology.

[5]  T. Sawada,et al.  Serum CA 125 level as a predictor of peritoneal dissemination in patients with gastric carcinoma , 1998, Cancer.

[6]  P. Sugarbaker,et al.  Radiology of peritoneal carcinomatosis. , 1996, Cancer treatment and research.

[7]  N. Kim,et al.  Clinical significance of primary tumor resection in colorectal cancer patients with synchronous unresectable metastasis , 2014, Journal of surgical oncology.

[8]  K. Tsuchiya,et al.  Factors influencing outcome after surgery for stage IV colorectal cancer , 2008, Surgery Today.

[9]  J. Hanley,et al.  The meaning and use of the area under a receiver operating characteristic (ROC) curve. , 1982, Radiology.

[10]  A. Hummon,et al.  Right‐side and left‐side colon cancer follow different pathways to relapse , 2012, Molecular carcinogenesis.

[11]  D. Elias,et al.  Linear Relationship of Peritoneal Cancer Index and Survival in Patients with Peritoneal Metastases from Colorectal Cancer , 2015, Annals of Surgical Oncology.

[12]  R. Bast,et al.  Tissue Distribution of a Coelomic- Epithelium‐Related Antigen Recognized by the Monoclonal Antibody OC125 , 1983, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[13]  T. Nishidate,et al.  Oncological benefit of primary tumor resection with high tie lymph node dissection in unresectable colorectal cancer with synchronous peritoneal metastasis: a propensity score analysis of data from a multi-institute database , 2015, International Journal of Clinical Oncology.

[14]  Mingxia Yu,et al.  Predictive value of serum CEA, CA19-9 and CA125 in diagnosis of colorectal liver metastasis in Chinese population. , 2013, Hepato-gastroenterology.

[15]  J. Clarke,et al.  Medicine , 1907, Bristol medico-chirurgical journal.

[16]  H. Egami,et al.  Clinical Significance of Serum CA125 Values in Patients with Cancers of the Digestive System , 1986, The American journal of the medical sciences.

[17]  G. Maddern,et al.  Does the primary site of colorectal cancer impact outcomes for patients with metastatic disease? , 2015, Cancer.

[18]  E. Montgomery,et al.  Mucin 16 (cancer antigen 125) expression in human tissues and cell lines and correlation with clinical outcome in adenocarcinomas of the pancreas, esophagus, stomach, and colon. , 2012, Human pathology.

[19]  R. Bast,et al.  Reactivity of a monoclonal antibody with human ovarian carcinoma. , 1981, The Journal of clinical investigation.

[20]  Shung-Haur Yang,et al.  Improved outcomes of colorectal cancer patients with liver metastases in the era of the multidisciplinary teams , 2016, International Journal of Colorectal Disease.

[21]  Shung-Haur Yang,et al.  Primary tumor location is an important predictive factor for wild‐type KRAS metastatic colon cancer treated with cetuximab as front‐line bio‐therapy , 2016, Asia-Pacific journal of clinical oncology.